Renal artery stenosis resident survival guide: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 19: | Line 19: | ||
* [[Common cause 5]] | * [[Common cause 5]] | ||
== | ==Clinical Clues to the Diagnosis of RAS== | ||
{{familytree/start}} | |||
{{familytree/start | {{familytree | | | A01 | | | A01= ❑ '''Determine if one or more of the above is present'''}} | ||
{{familytree | | | | {{familytree | | | |!| | | }} | ||
{{familytree | | | | | {{familytree | | | A02 | | A02= <table class="wikitable"> | ||
{{familytree | | | | |||
<tr class="v-firstrow"><th>Scenario</th><th>Level of evidence</th></tr> | |||
<tr><td>'''1.'''Onset of hypertension before the age of 30 years or severe hypertension after the age of 55. </td><td>Class I; LOE B</td></tr> | |||
<tr><td>Heparin therapeutic dose</td><td>1-5 </td></tr> | |||
{{familytree | <tr><td>Heparin flushes</td><td>0.1-1 </td></tr> | ||
{{familytree | | |||
{{familytree | | | <tr><td>[[LMWH]] prophylactic or therapeutic dose</td><td>0.1-1 </td></tr> | ||
{{familytree | | | | | | |||
<tr><td>Cardiac surgery patients</td><td>1-3 </td></tr> | |||
<tr><td>'''Medical patients''' </td><td> </td></tr> | |||
<tr><td>Patients with [[malignacy]]</td><td>1 </td></tr> | |||
<tr><td>Heparin prophylactic or therapeutic dose</td><td>0.1-1 </td></tr> | |||
<tr><td>LMWH, prophylactic or therapeutic dose</td><td>0.6 </td></tr> | |||
<tr><td>Intensive care unit patients</td><td>0.4 </td></tr> | |||
<tr><td>Heparin flushes</td><td>< 0.1 </td></tr> | |||
<tr><td>Obstetrics patients</td><td> <0.1 </td></tr> | |||
</table>}} | |||
{{familytree | |,|-|^|-|.| | }} | |||
{{familytree | B01 | | B02 | B01=<div style="height: 1em; width: 25em; padding:1em;">'''Risk <1%''' </div>| B02= <div style="height: 1em; width: 25em; padding:1em;">'''Risk >1%''' </div>}} | |||
{{familytree | |!| | | |!| | }} | |||
{{familytree | C01 | | C02 | C01= <div style="float: left; text-align: left; height: 3em; width: 25em; padding:1em;">❑ Do not monitor platelet count </div>| C02= <div style="float: left; text-align: left; height: 3em; width: 25em; padding:1em;">❑ Monitor platelet count every 2 or 3 days from day 4 to day 14 (or until heparin is stopped) </div>}} | |||
{{familytree/end}} | {{familytree/end}} | ||
Algorithm based on the 2012 ACCP evidence based clinical practice guidelines.<ref name="pmid22315270">{{cite journal| author=Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S et al.| title=Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | journal=Chest | year= 2012 | volume= 141 | issue= 2 Suppl | pages= e495S-530S | pmid=22315270 | doi=10.1378/chest.11-2303 | pmc=PMC3278058 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22315270 }} </ref> | |||
<br> | |||
<br> | |||
==References== | ==References== | ||
Revision as of 05:51, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Karol Gema Hernandez, M.D. [2]
Definition
This section provides a short and straight to the point definition of the disease or symptom in one sentence.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
Clinical Clues to the Diagnosis of RAS
| ❑ Determine if one or more of the above is present | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
Risk <1% | Risk >1% | ||||||||||||||||||||||||||||||||||||
❑ Do not monitor platelet count | ❑ Monitor platelet count every 2 or 3 days from day 4 to day 14 (or until heparin is stopped) | ||||||||||||||||||||||||||||||||||||
Algorithm based on the 2012 ACCP evidence based clinical practice guidelines.[1]
References
- ↑ Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S; et al. (2012). "Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e495S–530S. doi:10.1378/chest.11-2303. PMC 3278058. PMID 22315270.